

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

1012825

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International BureauLITERATUUR  EEN

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  A61K 31/19	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/16200 <b>(43) International Publication Date:</b> 1 October 1992 (01.10.92)
<b>(21) International Application Number:</b> PCT/US92/02078 <b>(22) International Filing Date:</b> 20 March 1992 (20.03.92)  <b>(30) Priority data:</b> 672,577 20 March 1991 (20.03.91) US  <b>(71) Applicant:</b> THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, U.S. DEPARTMENT OF COMMERCE [US/US]; 5285 Port Royal Road, Springfield, VA 22161 (US).  <b>(72) Inventors:</b> TABOR, Edward ; 5 Barrington Fare, Rockville, MD 20850 (US). EPSTEIN, Jay, S. ; 1922 Foxhall Road, McLean, VA 22101 (US). HEWLETT, Indira, K. ; 13424 Bartlett Street, Rockville, MD 20853 (US).	<b>(74) Agents:</b> HOLMAN, John, Clarke et al.; Fleit, Jacobson, Cohn, Price, Holman & Stern, The Jenifer Building, 400 Seventh Street, N.W., Washington, DC 20004 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT VIRAL REPLICATION  <b>(57) Abstract</b>  Hydroxamic acid derivatives such as deferoxamine (a drug that is already approved by the Food and Drug Administration for treating iron toxicity in humans) are useful for the inhibition of HIV and other viruses.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT  
VIRAL REPLICATION

TECHNICAL FIELD

The present invention relates to an antiviral  
5 compound that inhibits viral replication, a  
pharmaceutical composition containing the compound and a  
method of using the compound to inhibit viral  
replication.

BACKGROUND OF THE INVENTION

10 Despite considerable research, very few drugs have  
been discovered that are useful in the treatment of viral  
infections. Most of the drugs that are useful are  
nucleoside analogues. At present, the only approved  
treatment for human immunodeficiency virus (HIV)  
15 infection is azidothymidine (AZT), a drug with  
substantial toxicity and less than optimal efficacy.  
Other drugs under study include dideoxyinosine (ddI) and  
dideoxycytosine (ddC). There is no approved drug for the  
treatment of any other human retroviral infection.

20 SUMMARY OF THE INVENTION

Accordingly, it is an object of the present  
invention to provide a method for inhibiting the growth  
of a virus by use of a compound that is low in toxicity,  
but which also exhibits a significant anti-viral effect.  
25 Specifically, the present invention is directed to a  
method for inhibiting the growth of a virus, preferably  
a virus that is dependent on reverse transcriptase for  
replication, and method which comprises providing to a  
cell infected with the virus an effective viral growth  
30 inhibiting amount of a hydroxamic acid derivative having  
antiviral activity or a physiologically acceptable salt  
thereof or a physiologically acceptable chelate thereof.  
The hydroxamic acid derivative can be provided to cells  
growing in vitro that are infected by a virus or can be

administered to a human (or animal) infected by a virus. It is also possible that the hydroxamic acid derivative could be administered to a human (or animal) who is at high risk of being exposed to a virus in order to prevent viral replication upon such exposure.

In the treatment of individuals infected with HIV, the hydroxamic acid derivative can be administered to the human as soon as such a diagnosis has been made (such as by a positive immune response to HIV) or it can be administered after symptoms of the infection have appeared, i.e., after the patient has symptoms of Acquired Immunodeficiency Syndrome (AIDS) or AIDS-Related Complex (ARC).

#### DETAILED DESCRIPTION OF THE INVENTION

The hydroxamic acid derivatives that are useful in accordance with this invention include, but are not limited to, deferoxamine (also called desferrioxamine) (N-[5-[3-[(5-aminopentyl)-hydroxycarbamoyl]propionamido]-pentyl]-3-[[5-(N-hydroxyacetamido)-pentyl]carbamoyl]propiono-hydroxamic acid); salicylhydroxamic acid; hexanohydroxamic acid; octanohydroxamic acid; decanohydroxamic acid; dodecanohydroxamic acid; nicotinohydroxamic acid; o-aminobenzohydroxamic acid; rhodotorulic acid; and cholyhydroxamic acid; or a physiologically acceptable salt thereof or a physiologically acceptable chelate thereof. A preferred hydroxamic acid derivative is deferoxamine (DFX) which, when administered to a patient, is preferably administered in the form of a physiologically acceptable salt such as deferoxamine mesylate (Ciba-Geigy).

DFX is an iron-chelating compound that has recently been shown to have a significant inhibitory effect on the

growth in vitro of cell lines created from human hepatocellular carcinoma (HCC) (Hann et al, Hepatology, 11:566-569 (1990); Tabor et al, J. of Medical Virology (1991) (in press)), human neuroblastoma (Blatt et al, 5 Cancer Research, 49:2925-2927 (1989)), human lymphoma (Becton et al, Cancer Research, 49:4809-4812 (1989)), and human leukemia (Becton et al, Cancer Research, 49:4809-4812 (1989)).

The antiviral activity of hydroxamic acid derivatives, of which DFX is an example, against HIV-1, 10 strain HTLV-III<sub>8</sub>, in vitro (in H9 cells) has been established. Hydroxamic acid derivatives such as DFX may be active against a number of different viruses in vitro and in vivo and in particular it can be expected that 15 hydroxamic acid derivatives such as DFX may be active in vitro and in vivo against any virus whose replication is dependent on reverse transcriptase including HIV such as HIV-1 and HIV-2 and at least all members of the retrovirus family such as human T-lymphotropic virus 20 (HTLV) including HTLV-I (the causative agent for adult T-cell leukemia/lymphoma and related syndromes) and HTLV-II. Hepatitis B virus also uses an unusual reverse transcriptase mechanism of replication and the drug should be effective against it as well.

25 Hydroxamic acid derivatives may also have antiviral activity against other viruses which do not utilize reverse transcriptase. DFX has been shown to have a relatively low level of cytotoxicity against non-cancerous cells. For example, DFX is not usually toxic 30 in humans treated for iron toxicity and is not toxic against H9 cells as apparent from the studies reported herein. However, DFX does inhibit growth of cancer cells but it should not be characterized as cytotoxic.

DFX can form a chelate with iron or with a number of other metal ions or other cations. This happens after it has been administered to a patient, and this is a goal of the currently approved use of DFX. It is possible that  
5 DFX or other hydroxamic acid derivatives could be administered for antiviral purposes as a chelate. It is possible that the action as an antiviral occurs either in the form administered or after it has formed a chelate.

Hydroxamic acid derivatives could be used for the  
10 treatment and/or prophylaxis of human and animal viral diseases, particularly mammalian diseases, caused by the above-mentioned viruses and possibly other viruses. It is contemplated that the hydroxamic acid derivative will be formulated into a pharmaceutical composition  
15 comprising an effective antiviral amount of the hydroxamic acid derivative or physiologically acceptable salt or chelate thereof and a pharmaceutically acceptable carrier. For intravenous administration, the hydroxamic acid derivative could be administered without a carrier.  
20 An effective antiviral amount of the pharmaceutical composition will be administered to the subject, human, animal or mammal, in a manner and dose that inhibit or prevent viral replication. The amount of the hydroxamic acid derivative or physiologically acceptable salt or  
25 chelate thereof and the specific pharmaceutically acceptable carrier will vary depending upon the mode of administration and the type of viral condition being treated.

The routes of administration should be intravenous  
30 (i.v.), intraperitoneal (i.p.), or intramuscular (i.m.), subcutaneous (s.c.), or intradermal (i.d.), with i.v. and i.m. being preferred. The compound could be administered orally (p.o.) when it has been made in an appropriate



form for oral administration.

For localized virus infections, the pharmaceutical compositions may be administered topically as an ointment, cream, aerosol, or powder, or given as eye or  
5 nose drops, etc.

It can also be administered as a suppository.

In a particular aspect the pharmaceutical composition comprises the hydroxamic acid derivative or a physiologically acceptable salt or chelate thereof in  
10 effective unit dosage form. As used herein the term "effective unit dosage" or "effective unit dose" is denoted to mean a predetermined antiviral amount sufficient to be effective against the viruses in vivo. Pharmaceutically acceptable carriers are materials useful  
15 for the purpose of administering the compound, which are preferably non-toxic, and may be solid, liquid or gaseous materials, which are otherwise inert and medically acceptable and are compatible with the active ingredients. Preservatives may also be included in the  
20 formulation. The pharmaceutical compositions may be formulated with one active ingredient (the hydroxamic acid derivative or physiologically acceptable salt or chelate thereof) or in combination with other active ingredients such as other antiviral agents.

25 The compositions of DFX may contain 0.1%-99% by weight of the active material. For i.v. administration the preferred concentration is 0.1% to 25% weight/volume (w/v). For other parenteral routes, the preferred concentration is 0.1% to 50% w/v.

30 For oral administration, fine powders or granules may contain diluting, dispersing and/or surface active agents, and may be presented in a draught, in water or in a syrup; in capsules in the dry state or in a non-aqueous

solution or suspension, wherein suspending agents may be included; in tablets, wherein binders and lubricants may be included; in caplets; in micronized "sprinkle" form; or in a suspension in water or a syrup. Where desirable  
5 or necessary, flavoring, preserving, suspending, thickening or emulsifying agents may be included. Tablets and granules may be coated. For buccal administration the compositions may take the form of tablets or lozenges formulated in a conventional manner.

10 For administration as drops, as for eye infections, the compounds may be presented in aqueous solution in a concentration of from about 0.1 to 30%, more preferably 0.5 to 2.0%, most preferably 0.5% to 1.5% w/v. The solution may contain antioxidants, buffers,  
15 preservatives, etc.

The compounds according to the invention may also be formulated for injection and may be presented in unit dose form in ampoules or in multi-dose containers with an added preservative. The compositions may take such forms  
20 as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g.,  
25 sterile, pyrogen-free water, before use.

The compounds may be included in an aerosol or mist that is inhaled by a patient having a pulmonary infection or a systemic viral infection.

The compounds may be administered by intrathecal  
30 administration for treatment of a central nervous system (CNS) HIV or HTLV infection or other viral infections of the CNS.

The compounds may be applied into any body orifice such as the nose, oral cavity and ears, in the form of a spray or drops. They may be applied into body orifices in the form of a suppository or cream.

5 For systemic administration the daily dosage as employed for adult or pediatric human treatment will range from 0.1-200 mg/kg/day, preferably 1 to 10 mg/kg/day, which may be administered in 1 to 6 daily doses, for example, depending on the route of  
10 administration and the condition of the patient. When the compositions comprise dosage units, each unit will preferably contain 2 mg to 100 mg of active ingredient. For serious infections the compound may be administered by intravenous infusion using, for example, 0.01 to 10  
15 mg/kg/hr of the active ingredient (the i.v. administration not to exceed 15 mg/kg/hr).

In yet a further aspect of the invention there is provided a method of treating or preventing viral infections in animals (particularly mammals) or humans,  
20 which comprises the administration of an effective antiviral amount, as hereinbefore defined, of a hydroxamic acid derivative or a physiologically acceptable salt or physiologically acceptable chelate thereof.

25 In yet a further aspect of the invention, there is provided a pharmaceutical composition in unit dosage form wherein each unit dose contains 1 to 250 mg of active ingredient, preferably 2-100 mg of active ingredient. For example, 1 to 250 mg of the active ingredient can be  
30 placed in a sterile container such as a vial together with a pharmaceutically acceptable injectable diluent.

The compound should be administered in an amount calculated to produce a blood level of at least 30  $\mu$ M,

preferably 30 to 60  $\mu\text{M}$ , for a period of one to thirty days or longer. The compound of the present invention can be administered to the patient either alone or in combination with other antiviral compounds such as AZT.

- 5 When given in combination with other antiviral compounds, a lower blood level may be effective.

EXAMPLE

Duplicate cultures of H9 cells ( $5 \times 10^5$  cells/ml) infected with human immunodeficiency virus type 1 (HIV-1) (strain HTLV-III<sub>B</sub>) ( $10^4$  infectious units/ml) were maintained for 7 days in each of five coded media preparations, as shown in Table I. Cultures were split 1:2 at day 3. At day 7, coded samples of supernates were tested for HIV p24 antigen using a commercial capture enzyme immunoassay (Coulter Immunology, Hialeah, FL); coded samples of DNA extracted from cell lysates were tested for HIV proviral DNA by polymerase chain reaction using primer pairs derived from the gag and env regions of the genome (Hewlett et al, J. AIDS, 3:714-720 (1990)).

- 20 In these blinded studies, DFX inhibited the expression of p24 antigen and significantly reduced the detectable levels of gag and env genes in H9 cell cultures after seven days. The inhibition was dose-dependent (as shown in Table I); 30  $\mu\text{M}$  DFX had the same effect on p24 expression as 187  $\mu\text{M}$  azidothymidine (AZT) (Boehringer-Mannheim) (50  $\mu\text{g/ml}$ ). Cultures grown in medium lacking DFX and AZT produced substantial concentrations of p24, and the signals for gag and env sequences were strongly positive. Viability of the H9 cells was >70% at day 7 in cultures grown in DFX and AZT, as well as in the control cultures. Three independent experiments were conducted with similar results for p24 expression. Evaluation of gag and env were available

only in one experiment. Data provided in Table I are from the two experiments conducted under code.

The mechanism of this inhibition is unknown. DFX has been shown to inhibit DNA synthesis in seven human  
5 cancer cell lines from three different organ systems (reviewed in Tabor et al, J. of Medical Virology (1991) (in press)). In PHA-stimulated lymphocytes, inhibition by DFX of DNA synthesis has been reported to be due to the inhibition of iron-dependent ribonucleotide reductase  
10 (Hoffbrand et al, British Journal of Haematology, 33:517-526 (1976)). DFX could have inhibited HIV-1 by interfering with the RNA-dependent DNA synthesis that occurs early in each infectious cycle.

The 30  $\mu$ M concentration of DFX is equivalent to the  
15 blood level theoretically reached with an intravenous dose of 99 mg in a human with a 5-liter blood volume, well below the maximum recommended dose for DFX in humans, 2.0 g i.v. DFX has been administered experimentally to nine adults at much higher doses, 150  
20 mg/kg/day for five days, without recognized adverse reactions (Donfrancesco et al, Cancer Research, 50:4929-4930 (1990)).

The observation of in vitro inhibition of HIV-1 by DFX reported here may suggest a new mechanism of viral  
25 inhibition.

Table I

<u>Experiment A</u>					<u>Exp. B.</u>	
					Cell	Cell
					Via-	Via-
Medium						
5	<u>Containing</u>	<u>p24*</u>	<u>gag*</u>	<u>env*</u>	<u>bility*</u>	<u>p24*</u> <u>bility*</u>
	30 $\mu$ M DFX***	90	+	-	80%	0 95%
	20 $\mu$ M DFX	230	++	+	82%	0 70%
	10 $\mu$ M DFX	1174	++	+	75%	370 74%
	187 $\mu$ M AZT	117	-	-	78%	0 86%
10	Distilled					
	H <sub>2</sub> O**	1174	++	+	87%	400 79%
* p24 (pg/ml) by capture enzyme immunoassay of supernate; gag and env in DNA extracted from cell lysates and analyzed by polymerase chain reaction, scored visually on an autoradiogram on a scale from - to +++ by comparison with reference standards (Hewlett et al, J. AIDS, 3:714-720 (1990)); cell viability determined by trypan blue exclusion.						
15						
** Distilled water was added to the control medium in the same volume (0.25%) as the deferoxamine was added to create a 30 $\mu$ M solution.						
20						
*** In this Example, DFX was in the form of deferoxamine mesylate.						

CLAIMS:

1. Use of a hydroxamic acid derivative having antiviral activity or a physiologically acceptable salt thereof or a physiologically acceptable chelate thereof  
5 for the inhibition of the growth of a virus wherein an effective viral growth inhibiting amount of said hydroxamic acid derivative is provided to a cell infected with said virus.
2. Use according to claim 1, wherein said  
10 hydroxamic acid derivative is selected from the group consisting of deferroxamine; salicylhydroxamic acid; hexanohydroxamic acid; octanohydroxamic acid; decanohydroxamic acid; dodecanohydroxamic acid; nicotinohydroxamic acid; o-aminobenzohydroxamic acid;  
15 rhodotorulic acid; cholyhydroxamic acid;  
or a physiologically acceptable salt thereof or a physiologically acceptable chelate thereof.
3. Use according to claim 1, wherein deferroxamine mesylate is contacted with cells in vitro.
- 20 4. Use according to claim 1, wherein deferroxamine mesylate is administered to a human.
5. Use according to claim 1, wherein said virus is one that is dependent on reverse transcriptase for replication.
- 25 6. Use according to claim 1, wherein said virus is one that is not dependent on reverse transcriptase for replication.
7. Use according to claim 1, wherein deferroxamine mesylate is administered to a human infected with a virus  
30 that is dependent on reverse transcriptase for replication.
8. Use according to claim 1, wherein deferroxamine mesylate is administered to a human infected with a virus

that is not dependent on reverse transcriptase for replication.

9. Use according to claim 4, wherein said human is infected with human immunodeficiency virus.

5        10. Use according to claim 9, wherein said human has acquired immunodeficiency syndrome or AIDS-related complex.

11. Use according to claim 4, wherein said human is infected with hepatitis B virus.

10       12. Use according to claim 4, wherein said human is infected with HTLV.

13. Use according to claim 1, wherein said hydroxamic acid derivative or physiologically acceptable salt or physiologically acceptable chelate thereof is  
15 administered to an animal infected with a virus that is dependent on reverse transcriptase for replication.

14. Use according to claim 1, wherein said hydroxamic acid derivative or physiologically acceptable salt or physiologically acceptable chelate thereof is  
20 administered to an animal infected with a virus that is not dependent on reverse transcriptase for replication.

15. Use of a hydroxamic acid derivative or a physiologically acceptable salt or a physiologically acceptable chelate thereof for the prevention of viral  
25 replication wherein said hydroxamic acid derivative is administered to a subject that is at high risk of being exposed to a pathogenic virus in order to prevent viral infection.

16. An antiviral composition in unit dosage form  
30 comprising an effective antiviral amount, between 1 and 250 mg, of a hydroxamic acid derivative or a physiologically acceptable salt thereof or a physiologically acceptable chelate thereof.



17. The antiviral composition of claim 16, which comprises between 2 and 100 mg of deferoxamine mesylate packaged in a sterile vial.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/02078

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 31/19

US CL :514/575

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS &amp; CAS Online: hydroxamic acid, desferoxamine, viral, virus, antiviral, replication, reverse transcript?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Experientia, 15 February 1968, (GALE ET AL.), "Effects of Certain Hydroxamic Acids on Viral Replication", vol. 24, no. 2, pp. 194-195.	1-17
A	Cancer Research Effects of Desferoxamine on Human Myeloid Leukemia Cell Lines", vol. 49, pp. 4809-4812. 01 September 1989 (Becton et al.)	1-17
A	British Journal of Hematology, 1976,(Hoffbrand et al.), "Effect of Iron Deficiency and Desferrioxamine on DNA Synthesis in Human Cells", vol. 33, pp. 517-525.	1-17

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be part of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\*

document member of the same patent family

Date of the actual completion of the international search

03 AUGUST 1992

Date of mailing of the international search report

03 SEP 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

KIMBERLY JORDAN

Telephone No. (703) 308-4611

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/02078

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

Group I, claims 1-14, drawn to inhibiting viral growth with a hydroxamic acid derivative, classified in class 514, subclass 575.

Group III, claims 16-17, drawn to compositions of hydroxamic acid derivatives, classified in class 514, subclass 575.

Groups I-II are distinct from group III in that PCT Rule 13.1 does not provide for methods of using and composition within a single inventive concept. Group I is distinct from group II since they are drawn to distinct & distinct & separate methods.

Group II, claim 15, drawn to preventing viral replication with a hydroxamic acid derivative, classified in class 514, subclass 575.